Fibroblast growth factor 21: a role in cardiometabolic disorders and cardiovascular risk prediction?

In this issue of Metabolism, Ong et al [1] report that fibroblast growth factor 21 (FGF21) levels could predict major cardiovascular (CV) events (MCVE) in statin-treated patients with stable coronary heart disease (CHD) using data from the Treating to New Targets (TNT) trial (n  = 10,001; median follow-up = 4.9 years) [2]; MCVE were defined as a composite of CHD death, cardiac arrest, fatal or non-fatal stroke and non-fatal myocardial infarction (MI). In the Ong et al study [1], 1996 patients with plasma FGF21 concentrations available at baseline were analyzed; 1 835 of them had also FGF21 measurements at the 1-year timepoint.
Source: Metabolism - Clinical and Experimental - Category: Biomedical Science Authors: Source Type: research